Activation of ERK in the context of acquired CDK4i/6i-resistance has not been reported in melanoma, however evidence in the breast cancer literature proposes a role for de novo HER2 mutations in estrogen receptor positive (ER+) breast cancers [23]. The gene discussed is ERBB2; the disease is breast carcinoma.